Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.43590 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Cataldo Patruno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Prurigo, Drug Costs. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Prurigo nodularis is characterized by intensely pruritic nodules that significantly impact patients’ quality of life. This study aims to evaluate the cost-effectiveness of dupilumab compared with the best supportive care for the treatment of severe prurigo nodularis from the perspective of the Italian National Health Service. A cost-effectiveness model was developed using a decision tree followed by a Markov approach with a lifetime horizon (30 years). Baseline characteristics, efficacy, and utility data were derived from the pooled analysis of PRIME and PRIME2 trials. Direct healthcare costs based on drug acquisition, adverse event and complications management, and disease-related healthcare resource utilization were considered. Dupilumab improved health outcomes, with an incremental gain of 1.481 quality-adjusted life-years compared with best supportive care. The total cost of dupilumab treatment was €148,964, compared with €70,957 for the best supportive care arm, thus resulting in an incremental cost-effectiveness ratio of €52,661 per quality-adjusted life-year. Scenario analyses indicated that at a discount ≥ 20%, the incremental cost-effectiveness ratio was lower than €40,000/quality-adjusted life-year. Deterministic and probabilistic sensitivity analyses confirmed the robustness of the results. Dupilumab is likely to be a cost-effective treatment for severe prurigo nodularis patients eligible for systemic therapy in Italy, as it reduces disease burden and healthcare costs associated with uncontrolled prurigo nodularis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso Italy.
- AdRes Health Economics and Outcomes Research, Turin, Italy. m.povero@adreshe.com.
- Sanofi Italia, Milan, Italy.
- Sanofi, Gentilly, France.
- Dermatologic Clinic, G. D'Annunzio University, Chieti, Italy.
ORCID-Profile: Cataldo Patruno
Zitieren
APA
Patruno, C., Povero, M., Tassone, A., Pedone, M. P., Bahloul, D., Tavi, J., & Amerio, P. (2025). Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.43590
Vancouver
Patruno C, Povero M, Tassone A, Pedone MP, Bahloul D, Tavi J, et al. Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.43590
BibTeX
@article{Patruno2025,
author = {Patruno, Cataldo and Povero, Massimiliano and Tassone, Andrea and Pedone, Maria Paola and Bahloul, Donia and Tavi, Jules and Amerio, Paolo},
title = {Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.43590}
}
EUVIMED